- Home
- HOLO vs ATNM Comparison
HOLO vs ATNM Comparison
Compare HOLO & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOLO
- ATNM
- Stock Information
- Founded
- HOLO 2018
- ATNM 2000
- Country
- HOLO China
- ATNM United States
- Employees
- HOLO N/A
- ATNM N/A
- Industry
- HOLO Computer Software: Programming Data Processing
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- HOLO Technology
- ATNM Health Care
- Exchange
- HOLO Nasdaq
- ATNM Nasdaq
- Market Cap
- HOLO 50.1M
- ATNM 56.5M
- IPO Year
- HOLO N/A
- ATNM N/A
- Fundamental
- Price
- HOLO $1.70
- ATNM $1.40
- Analyst Decision
- HOLO
- ATNM Strong Buy
- Analyst Count
- HOLO 0
- ATNM 4
- Target Price
- HOLO N/A
- ATNM $8.75
- AVG Volume (30 Days)
- HOLO 41.2M
- ATNM 342.1K
- Earning Date
- HOLO 01-01-0001
- ATNM 11-14-2024
- Dividend Yield
- HOLO N/A
- ATNM N/A
- EPS Growth
- HOLO N/A
- ATNM N/A
- EPS
- HOLO N/A
- ATNM N/A
- Revenue
- HOLO $32,242,196.00
- ATNM $81,000.00
- Revenue This Year
- HOLO N/A
- ATNM $138.42
- Revenue Next Year
- HOLO N/A
- ATNM $19,479.88
- P/E Ratio
- HOLO N/A
- ATNM N/A
- Revenue Growth
- HOLO 326.95
- ATNM N/A
- 52 Week Low
- HOLO $1.23
- ATNM $1.10
- 52 Week High
- HOLO $1,968.00
- ATNM $10.24
- Technical
- Relative Strength Index (RSI)
- HOLO 43.08
- ATNM 56.03
- Support Level
- HOLO $2.11
- ATNM $1.18
- Resistance Level
- HOLO $2.50
- ATNM $1.48
- Average True Range (ATR)
- HOLO 1.30
- ATNM 0.10
- MACD
- HOLO -0.21
- ATNM 0.01
- Stochastic Oscillator
- HOLO 0.53
- ATNM 75.00
About HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.